色谱

• 技术与应用 • 上一篇    下一篇

一种抗偏头痛复方制剂体外溶出度的比较研究

HIREMATH Vijay Basayya1, KALIAPERUMAL Krishna1, BHOJRAJ Suresh2, NANJAN Mulla Joghee1*   

  1. 1.TIFAC CORE HD, JSS College of Pharmacy, Rocklands, Ooty-643001, Tamilnadu, India; 2.JSS University, Banimantap, Mysore, Karnataka, India
  • 收稿日期:2009-04-10 修回日期:2009-06-10 出版日期:2010-01-28 发布日期:1981-09-25
  • 通讯作者: NANJAN Mulla Joghee

In vitro dissolution profile comparison of an anti-migraine combinational drug in dosage form

HIREMATH Vijay Basayya1, KALIAPERUMAL Krishna1, BHOJRAJ Suresh2, NANJAN Mulla Joghee1*   

  1. 1.TIFAC CORE HD, JSS College of Pharmacy, Rocklands, Ooty-643001, Tamilnadu, India; 2.JSS University, Banimantap, Mysore, Karnataka, India
  • Received:2009-04-10 Revised:2009-06-10 Online:2010-01-28 Published:1981-09-25
  • Contact: NANJAN Mulla Joghee

摘要: A novel in vitro dissolution profile was developed for formulated drug in combinational form containing naproxen sodium (NAP) and sumatriptan succinate (SUMA). This study was performed to understand the dissolution of the drug in the physiological temperature and pH. Dissolution testing was performed using USP 29 type II testing apparatus rotating at 50 r/min, in 900 mL deaerated buffer (pH 1.2, 4.5 and 6.8) which was maintained at (37±0.5) ℃. Quantification was performed using a developed and validated high performance liquid chromatographic (HPLC) method. Aceclofenac (ACE) was used as internal standard. SUMA, ACE and NAP were eluted at 4.8, 5.7 and 7.9 min, respectively. As expected for enteric coated immediate release (IR) tablets, the dissolution of NAP and SUMA was rapid and essentially complete within 2 h using phosphate buffer (pH 6.8). The comparison of the dissolution profiles was realized by model independent approach using a difference factor (f1), similarity factor (f2) and dissolution efficiency (DE). Statistical results showed the profiles were similar to the reference and the test products. Hence, this method demonstrated to be adequate for in vitro studies of NAP and SUMA in the combinational dosage form, since there is no official monograph, collaborating to the official codes.

关键词: dissolution method development, naproxen sodium, sumatriptan succinate , in vitro dissolution profiles

Abstract: A novel in vitro dissolution profile was developed for formulated drug in combinational form containing naproxen sodium (NAP) and sumatriptan succinate (SUMA). This study was performed to understand the dissolution of the drug in the physiological temperature and pH. Dissolution testing was performed using USP 29 type II testing apparatus rotating at 50 r/min, in 900 mL deaerated buffer (pH 1.2, 4.5 and 6.8) which was maintained at (37±0.5) ℃. Quantification was performed using a developed and validated high performance liquid chromatographic (HPLC) method. Aceclofenac (ACE) was used as internal standard. SUMA, ACE and NAP were eluted at 4.8, 5.7 and 7.9 min, respectively. As expected for enteric coated immediate release (IR) tablets, the dissolution of NAP and SUMA was rapid and essentially complete within 2 h using phosphate buffer (pH 6.8). The comparison of the dissolution profiles was realized by model independent approach using a difference factor (f1), similarity factor (f2) and dissolution efficiency (DE). Statistical results showed the profiles were similar to the reference and the test products. Hence, this method demonstrated to be adequate for in vitro studies of NAP and SUMA in the combinational dosage form, since there is no official monograph, collaborating to the official codes.

Key words: dissolution method development, naproxen sodium, sumatriptan succinate , in vitro dissolution profiles